IOL Chemicals and Pharmaceuticals Limited (IOLCP.BO)
INR 60.95
(1.96%)
INR 60.95
(1.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.1 Billion INR | -240.44% |
| 2022 | 784.2 Million INR | 92.58% |
| 2021 | 407.2 Million INR | 237.52% |
| 2020 | -296.1 Million INR | -194.3% |
| 2019 | 314 Million INR | -88.4% |
| 2018 | 2.7 Billion INR | -35.75% |
| 2017 | 4.21 Billion INR | -5.31% |
| 2016 | 4.44 Billion INR | -1.26% |
| 2015 | 4.5 Billion INR | 16.1% |
| 2014 | 3.87 Billion INR | 26.82% |
| 2013 | 3.05 Billion INR | -17.68% |
| 2012 | 3.71 Billion INR | 10.05% |
| 2011 | 3.37 Billion INR | 55.53% |
| 2010 | 2.17 Billion INR | -17.3% |
| 2009 | 2.62 Billion INR | 15.99% |
| 2008 | 2.26 Billion INR | 136.77% |
| 2007 | 955.9 Million INR | -3.47% |
| 2006 | 990.28 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | 558.2 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | -1.1 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | -1.1 Billion INR | -240.44% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 784.2 Million INR | 92.58% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 784.2 Million INR | 0.0% |
| 2022 Q2 | 750.3 Million INR | 0.0% |
| 2021 Q2 | 259.3 Million INR | 0.0% |
| 2021 Q1 | - INR | 100.0% |
| 2021 FY | 407.2 Million INR | 237.52% |
| 2021 Q4 | 407.2 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | -296.1 Million INR | 0.0% |
| 2020 Q2 | 152.8 Million INR | 0.0% |
| 2020 FY | -296.1 Million INR | -194.3% |
| 2019 FY | 314 Million INR | -88.4% |
| 2019 Q4 | 314 Million INR | 0.0% |
| 2019 Q2 | 360.2 Million INR | 0.0% |
| 2018 FY | 2.7 Billion INR | -35.75% |
| 2018 Q4 | 2.7 Billion INR | 0.0% |
| 2018 Q2 | 3.48 Billion INR | 0.0% |
| 2017 Q4 | 4.21 Billion INR | 0.0% |
| 2017 FY | 4.21 Billion INR | -5.31% |
| 2017 Q2 | 4.24 Billion INR | 0.0% |
| 2016 Q2 | 4.16 Billion INR | 0.0% |
| 2016 Q4 | 4.44 Billion INR | 0.0% |
| 2016 FY | 4.44 Billion INR | -1.26% |
| 2015 Q2 | 4.17 Billion INR | 0.0% |
| 2015 Q4 | 4.5 Billion INR | 0.0% |
| 2015 FY | 4.5 Billion INR | 16.1% |
| 2014 Q2 | 3.1 Billion INR | 0.0% |
| 2014 Q4 | 3.87 Billion INR | 0.0% |
| 2014 FY | 3.87 Billion INR | 26.82% |
| 2013 FY | 3.05 Billion INR | -17.68% |
| 2013 Q4 | 3.05 Billion INR | 0.0% |
| 2013 Q2 | 3.58 Billion INR | 0.0% |
| 2012 Q4 | 3.71 Billion INR | 0.0% |
| 2012 FY | 3.71 Billion INR | 10.05% |
| 2012 Q2 | 4.96 Billion INR | 0.0% |
| 2011 FY | 3.37 Billion INR | 55.53% |
| 2010 FY | 2.17 Billion INR | -17.3% |
| 2009 FY | 2.62 Billion INR | 15.99% |
| 2008 FY | 2.26 Billion INR | 136.77% |
| 2007 FY | 955.9 Million INR | -3.47% |
| 2006 FY | 990.28 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 128.488% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 129.819% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 61.258% |
| Granules India Limited | 9.28 Billion INR | 111.859% |
| Indoco Remedies Limited | 6.47 Billion INR | 117.005% |
| Achyut Healthcare Limited | -3.74 Million INR | -29299.359% |
| Ajanta Pharma Limited | -954.9 Million INR | -15.331% |
| Alkem Laboratories Limited | -1.6 Billion INR | 31.571% |
| Alpa Laboratories Limited | 35.36 Million INR | 3214.272% |
| Brooks Laboratories Limited | 49.48 Million INR | 2325.523% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 78.029% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 133.383% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 4.876% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 108.529% |
| Eris Lifesciences Limited | 13.8 Billion INR | 107.977% |
| FDC Limited | -57.75 Million INR | -1806.947% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 74.3% |
| Gufic Biosciences Limited | 3.19 Billion INR | 134.477% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 73.482% |
| Ipca Laboratories Limited | 11.41 Billion INR | 109.648% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 20.766% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 156.976% |
| Lasa Supergenerics Limited | 205.79 Million INR | 635.134% |
| Laurus Labs Limited | 24.38 Billion INR | 104.516% |
| Lupin Limited | 17.19 Billion INR | 106.406% |
| Mankind Pharma Limited | -9.9 Billion INR | 88.885% |
| Medicamen Biotech Limited | 160.31 Million INR | 786.956% |
| Medico Remedies Limited | 78.67 Million INR | 1499.774% |
| Megasoft Limited | 1.28 Billion INR | 185.667% |
| NATCO Pharma Limited | -5.81 Billion INR | 81.068% |
| Piramal Pharma Limited | 42.27 Billion INR | 102.605% |
| RPG Life Sciences Limited | -364.7 Million INR | -201.974% |
| Sigachi Industries Limited | 859.94 Million INR | 228.066% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 98.48% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 859.643% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 2483.199% |
| Unichem Laboratories Limited | 931.91 Million INR | 218.176% |
| Wanbury Limited | 1.1 Billion INR | 199.586% |
| Windlas Biotech Limited | -273.04 Million INR | -303.347% |
| ZIM Laboratories Limited | 983.6 Million INR | 211.966% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 128.152% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -16.936% |
| Divi's Laboratories Limited | -39.77 Billion INR | 97.231% |
| Hester Biosciences Limited | 2.29 Billion INR | 148.076% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 53.096% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -342.659% |
| Bal Pharma Limited | 1.26 Billion INR | 187.158% |
| Strides Pharma Science Limited | 23.25 Billion INR | 104.735% |
| Venus Remedies Limited | -267.7 Million INR | -311.393% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 142.165% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 117.886% |
| Shilpa Medicare Limited | 9.06 Billion INR | 112.143% |
| Aarti Drugs Limited | 5.54 Billion INR | 119.849% |
| Suven Life Sciences Limited | -1.63 Billion INR | 32.547% |
| Ind-Swift Limited | 9.5 Billion INR | 111.582% |
| Valiant Laboratories Limited | -295.03 Million INR | -273.282% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 139.037% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 110.981% |
| Themis Medicare Limited | 764.96 Million INR | 243.968% |
| Hikal Limited | 7.96 Billion INR | 113.823% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 103.46% |
| Sequent Scientific Limited | 4.17 Billion INR | 126.356% |
| Novartis India Limited | -5.89 Billion INR | 81.306% |
| Wockhardt Limited | 18.27 Billion INR | 106.028% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 104.068% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -5870.4% |
| Neuland Laboratories Limited | -214.05 Million INR | -414.487% |
| Morepen Laboratories Limited | -231.17 Million INR | -376.394% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 1017.452% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 212.86% |